WithdrawnEarly Phase 1

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Stopped: No patients consented to enrollment

United States0Started 2022-08-01

Plain-language summary

The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. subjects within the claims dataset that are predicted to be at risk of having ATTR who are also being managed within YNHHS
✓. patients who need to be contacted and offered additional clinical evaluation to determine whether they have a diagnosis of ATTR (non-hereditary or Hereditary ATTR amyloidosis).

Diagnostic performance of algorithm in identifying patients with ATTR amyloidosis

Timeframe: 2 years

NCT IDNCT04569903

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-01